Funding Trends

Since 2004, The Working Group has tracked data on investment in HIV prevention research and development (R&D1). Our analysis allows comparison across years, prevention options, sectors, and countries, supporting transparency on investment trends and contributing to a greater understanding of the trajectory and impact of policies, for funders and advocates alike2. These data are a vital resource for advocacy.

Overall Funding in 2019

Total investment in HIV biomedical prevention R&D in 2019 remained mostly unchanged from the previous year at US$1.14 billion. This reverses the upward swing observed in 2018 and continues the post-2012 trend of either declining or flat funding. Investment levels varied by prevention technology. Funding increased for preventive HIV vaccines, pre-exposure prophylaxis (PrEP) and female condoms; investment in all other evaluated technology categories declined from the previous year. For a detailed breakdown of the investment by technology category, please see this section

Mirroring past trends, 80 percent of global funding originated from the public sector at US$919 million, with the US contributing 94.6 percent of the total. European investments declined significantly, coming in at US$41 million in 2019—representing four percent of all public funding (see details below). Investments from all other countries came in at US$5.3 million, or one percent of overall public funding. Philanthropic investment decreased by three percent to US$158 million or 14 percent of total global funding, and commercial investments fell by five percent to US$71 million or 16 percent of the total. The only multilateral involved in HIV R&D, The World Bank Group, contributed investment figures in 2019 at US$2.5 million. The World Bank did not contribute to this report in the previous year, so this number does not represent an increase or decrease.

 
$ 0 B
increase in overall HIV prevention R&D funding in 2019

What are the historic and current trends for investment in HIV prevention R&D?

For Year:
0
US$ Million
icon
Preventative vaccines
0
US$ Million
icon
Microbicides
0
US$ Million
icon
Prevention of vertical transmission
0
US$ Million
icon
Pre-exposure prophylaxis
0
US$ Million
icon
Treatment as prevention
0
US$ Million
icon
Voluntary medical male circumcision
0
US$ Million
icon
Female Condoms

We are updating the 2019 numbers, please check back soon.

For Year:
0
US$ Million
icon
Multilateral Public Sector
0
US$ Million
icon
Europe - Public Sector
0
US$ Million
icon
US Public Sector
0
US$ Million
icon
Other Public Sector
0
US$ Million
icon
Wellcome Trust
0
US$ Million
icon
Bill & Melinda Gates Foundation
0
US$ Million
icon
Other Philanthropic
0
US$ Million
icon
Other Commercial

US Funding

US public sector investment rose by five percent in 2019, increasing from US$829 million in 2018 to US$871 million in 2019. The National Institutes of Health (NIH) had a five percent increase, from US$720 million to US$758 million. Funding by the Military HIV Research Program (MHRP) rose one percent to US$36 million and the Centers for Disease Control and Prevention (CDC) recorded a 31 percent increase with levels reaching US$2 million. The United States Agency for International Development (USAID) also had a one percent increase, from US$72 to US$73 million. US funding for preventive vaccines, PrEP and voluntary medical male circumcision (VMMC) increased in 2019. Investment decreased for all other tracked technologies and remained unchanged for microbicides. A full list of all the biomedical prevention technologies tracked by this analysis can be found here.
0 .0%
increase in US funding in 2019

European Funding

European public sector funding decreased by 29 percent from 2018 and, at US$41 million, is the lowest figure for European funding recorded in the last decade and a far cry from peak funding of US$124 million in 2009. Excluding R&D for treatment as prevention (TasP), which had a modest increase of US$0.8 million, European public investment in vaccines, microbicides, prevention of vertical transmission and PrEP declined by 22 percent, 33 percent, 12 percent and 71 percent, respectively. Furthermore, female condoms and VMMC lost all European investment in 2019.

29 %
decrease in European funding in 2019

Philanthropic Funding

Global philanthropic funding levels dipped in 2019, falling to US$158 million. While still the largest donor, accounting for 92 percent of all sector funding, the Bill & Melinda Gates Foundation (BMGF) lowered its contributions by 3 percent to US$145 million.The majority of BMGF investment was directed towards vaccines (69 percent) and PrEP (23 percent), with smaller disbursements for VMMC (five percent), microbicides (two percent) and prevention of vertical transmission (one percent). While the overwhelming majority of philanthropic funding originated from the US, European philanthropies like Institut Pasteur, Aidsfonds and the Swiss National Science Foundation continue to reliably fund HIV prevention and cure R&D.

3 .0%
decrease in philanthropic funding in 2019

Commercial Funding

Commercial funding for HIV prevention R&D decreased by five percent from 2018, falling to US$70.6 million. The Working Group evaluated funding from 10 companies, but commercial R&D investments likely far exceed what the Working Group has been able to review. Among commercial contributions the Working Group has evaluated, all areas of HIV prevention R&D have steadily increased for several years, as industry has played a larger role not only in product development, but also in providing funding and expertise for implementation and rollout.

5 .0%
decrease in commercial funding in 2019

Footnotes

  1. For the purposes of this report, the terms “research and development, or “R&D” and “research” are used interchangeably and all refer to the entire spectrum of research activities.
  2. See About Us for more information